DocMorris has been given a 'Sell' rating by UBS, with a price target of 27 francs, after the release of the company's third-quarter figures.
Sales were in line with expectations, but there may be a slightly negative reaction in the share price. DocMorris is falling behind its main German competitor in the prescription business, which could be a cause for concern among investors. The market is expected to respond to this competitive disadvantage.